Non-Hodgkin's lymphomas, version 2.2014

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasceAuayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie Marie Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

Original languageEnglish (US)
Pages (from-to)916-946
Number of pages31
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2014

Fingerprint

Follicular Lymphoma
Non-Hodgkin's Lymphoma
Radioimmunotherapy
Therapeutics
Lymphoproliferative Disorders
Standard of Care
Natural Killer Cells
Disease-Free Survival
B-Lymphocytes
Maintenance
Guidelines
T-Lymphocytes
Recurrence
Drug Therapy
Rituximab

ASJC Scopus subject areas

  • Oncology

Cite this

Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., ... Sundar, H. (2014). Non-Hodgkin's lymphomas, version 2.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(6), 916-946. https://doi.org/10.6004/jnccn.2014.0086

Non-Hodgkin's lymphomas, version 2.2014. / Zelenetz, Andrew D.; Gordon, Leo I.; Wierda, William G.; Abramson, Jeremy S.; Advani, Ranjana H.; Andreadis, C. Babis; Bartlett, Nancy; Bellam, Naresh; Byrd, John C.; Czuczman, Myron S.; Fayad, Luis E.; Fisher, Richard I.; Glenn, Martha J.; Harris, Nancy Lee; Hoppe, Richard T.; Horwitz, Steven M.; Kelsey, Christopher R.; Kim, Youn H.; Krivacic, Susan; LaCasce, Ann S.; Nademanee, Auayporn; Porcu, Pierluigi; Press, Oliver; Rabinovitch, Rachel; Reddy, Nishitha; Reid, Erin; Sokol, Lubomir; Swinnen, Lode J.; Tsien, Christina; Vose, Julie Marie; Yahalom, Joachim; Zafar, Nadeem; Dwyer, Mary; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 6, 01.06.2014, p. 916-946.

Research output: Contribution to journalReview article

Zelenetz, AD, Gordon, LI, Wierda, WG, Abramson, JS, Advani, RH, Andreadis, CB, Bartlett, N, Bellam, N, Byrd, JC, Czuczman, MS, Fayad, LE, Fisher, RI, Glenn, MJ, Harris, NL, Hoppe, RT, Horwitz, SM, Kelsey, CR, Kim, YH, Krivacic, S, LaCasce, AS, Nademanee, A, Porcu, P, Press, O, Rabinovitch, R, Reddy, N, Reid, E, Sokol, L, Swinnen, LJ, Tsien, C, Vose, JM, Yahalom, J, Zafar, N, Dwyer, M & Sundar, H 2014, 'Non-Hodgkin's lymphomas, version 2.2014', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 6, pp. 916-946. https://doi.org/10.6004/jnccn.2014.0086
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB et al. Non-Hodgkin's lymphomas, version 2.2014. JNCCN Journal of the National Comprehensive Cancer Network. 2014 Jun 1;12(6):916-946. https://doi.org/10.6004/jnccn.2014.0086
Zelenetz, Andrew D. ; Gordon, Leo I. ; Wierda, William G. ; Abramson, Jeremy S. ; Advani, Ranjana H. ; Andreadis, C. Babis ; Bartlett, Nancy ; Bellam, Naresh ; Byrd, John C. ; Czuczman, Myron S. ; Fayad, Luis E. ; Fisher, Richard I. ; Glenn, Martha J. ; Harris, Nancy Lee ; Hoppe, Richard T. ; Horwitz, Steven M. ; Kelsey, Christopher R. ; Kim, Youn H. ; Krivacic, Susan ; LaCasce, Ann S. ; Nademanee, Auayporn ; Porcu, Pierluigi ; Press, Oliver ; Rabinovitch, Rachel ; Reddy, Nishitha ; Reid, Erin ; Sokol, Lubomir ; Swinnen, Lode J. ; Tsien, Christina ; Vose, Julie Marie ; Yahalom, Joachim ; Zafar, Nadeem ; Dwyer, Mary ; Sundar, Hema. / Non-Hodgkin's lymphomas, version 2.2014. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 6. pp. 916-946.
@article{5979be8723fc434aaef221108267e684,
title = "Non-Hodgkin's lymphomas, version 2.2014",
abstract = "Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22{\%} of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.",
author = "Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Wierda, {William G.} and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Andreadis, {C. Babis} and Nancy Bartlett and Naresh Bellam and Byrd, {John C.} and Czuczman, {Myron S.} and Fayad, {Luis E.} and Fisher, {Richard I.} and Glenn, {Martha J.} and Harris, {Nancy Lee} and Hoppe, {Richard T.} and Horwitz, {Steven M.} and Kelsey, {Christopher R.} and Kim, {Youn H.} and Susan Krivacic and LaCasce, {Ann S.} and Auayporn Nademanee and Pierluigi Porcu and Oliver Press and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Lubomir Sokol and Swinnen, {Lode J.} and Christina Tsien and Vose, {Julie Marie} and Joachim Yahalom and Nadeem Zafar and Mary Dwyer and Hema Sundar",
year = "2014",
month = "6",
day = "1",
doi = "10.6004/jnccn.2014.0086",
language = "English (US)",
volume = "12",
pages = "916--946",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "6",

}

TY - JOUR

T1 - Non-Hodgkin's lymphomas, version 2.2014

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Wierda, William G.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Andreadis, C. Babis

AU - Bartlett, Nancy

AU - Bellam, Naresh

AU - Byrd, John C.

AU - Czuczman, Myron S.

AU - Fayad, Luis E.

AU - Fisher, Richard I.

AU - Glenn, Martha J.

AU - Harris, Nancy Lee

AU - Hoppe, Richard T.

AU - Horwitz, Steven M.

AU - Kelsey, Christopher R.

AU - Kim, Youn H.

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Nademanee, Auayporn

AU - Porcu, Pierluigi

AU - Press, Oliver

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Sokol, Lubomir

AU - Swinnen, Lode J.

AU - Tsien, Christina

AU - Vose, Julie Marie

AU - Yahalom, Joachim

AU - Zafar, Nadeem

AU - Dwyer, Mary

AU - Sundar, Hema

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

AB - Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.

UR - http://www.scopus.com/inward/record.url?scp=84902504593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902504593&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0086

DO - 10.6004/jnccn.2014.0086

M3 - Review article

C2 - 24925202

AN - SCOPUS:84902504593

VL - 12

SP - 916

EP - 946

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 6

ER -